Bradley Pharmaceuticals Announces Appointment of Dr. Leonard S. Jacob As Non-Executive Chair

12-Jan-2007

Bradley Pharmaceuticals, Inc. announced that the Board of Directors has elected Leonard S. Jacob, M.D., Ph.D., as its non-executive Chairman of the Board, separating the positions of Chairman of the Board and CEO. Dr. Jacob joined the Bradley Board in February 2006 and had been Chairman of Bradley's Nominating and Corporate Governance Committee. Daniel Glassman will continue to lead the Company as its CEO and President and also will continue to serve as a member of the Board.

Leonard S. Jacob, M.D., Ph.D., founded InKine Pharmaceutical Company, Inc. in 1997 and served as Chairman and CEO from its founding until the company was acquired by Salix Pharmaceuticals in September 2005. In 1989, Dr. Jacob co- founded Magainin Pharmaceuticals and served as its Chief Operating Officer until 1996. From 1980 to 1989, Dr. Jacob served in a variety of executive roles, including Worldwide Vice President of SmithKline & French Labs (now Glaxo-SmithKline), and as a member of their Corporate Management Committee. Dr. Jacob currently serves as Chairman of Life Science Advisors, a consulting group to the healthcare industry, and on the Board of Directors for the Colon Cancer Alliance and the Board of Overseers for Temple University School of Medicine. Dr. Jacob also serves on the Board of Glyconix Corp., a private drug delivery company, and, until its sale in January 2007, Dr. Jacob served on the Board of MacroMed, Inc., a private drug delivery company. In addition, Dr. Jacob is a founding Director of the Jacob Internet Fund, a publicly traded mutual fund.

https://www.chemeurope.com/en/news/60722/bradley-pharmaceuticals-announces-appointment-of-dr-leonard-s-jacob-as-non-executive-chair.html